Evidence map›Paper›PMID 42496124›Full record

ArticleMicrobiology spectrum2026

Lanthipeptides from

Anastasia Lambropoulou, Jennifer Herrmann, Felix Deschner, Rolf Müller, Stathis D Kotsakis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anastasia LambropoulouLaboratory of Bacteriology, Hellenic Pasteur Institute, Athens, Greece.
Jennifer HerrmannHelmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Center for Infection Research and Department of Pharmacy of Saarland University, Saarbrücken, Germany.ORCID 0000-0003-3398-9938
Felix DeschnerHelmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Center for Infection Research and Department of Pharmacy of Saarland University, Saarbrücken, Germany.
Rolf MüllerHelmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Center for Infection Research and Department of Pharmacy of Saarland University, Saarbrücken, Germany.
Stathis D KotsakisLaboratory of Bacteriology, Hellenic Pasteur Institute, Athens, Greece.ORCID 0000-0002-5744-8258

Funding

Hellenic Pasteur Institute 7000/19-06-2020
6 · The paper itself

Abstract

During a screening of secondary metabolites produced by soil bacteria, we identified two lanthipeptides from IMPORTANCE: Resistance of clinical Enterobacterales to last resort drugs, such as carbapenems and newer cephalosporins, requires urgent measures. Production of metallo-β-lactamases is an important factor contributing to the problem, as there is no available therapeutic option against them. As with many of our currently utilized antibiotic classes, the environment has proven to be a valuable source of novel compounds, and naturally occurring inhibitors of metallo-β-lactamases may still await discovery. Herein, we show that such examples are two lanthipeptides produced by the soil bacterium

Indexed as

Anti-Bacterial Agentsbeta-Lactamasesbeta-LactamsEnterobacteriaceaePeptidesbeta Lactam AntibioticsDrug SynergismMicrobial Sensitivity TestsAnti-Bacterial Agentsbeta Lactam Antibioticsbeta-Lactamasesbeta-LactamsPeptidescarbapenemaseslanthipeptidesmetallo-β-lactamases

Identifiers

PMID42496124
PMCPMC13532221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.